KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Receivables - Net: 2013-2024

Historic Receivables - Net for Rigel Pharmaceuticals (RIGL) over the last 10 years, with Dec 2024 value amounting to $41.6 million.

  • Rigel Pharmaceuticals' Receivables - Net rose 50.20% to $45.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year increase of 50.20%. This contributed to the annual value of $41.6 million for FY2024, which is 36.22% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Receivables - Net stood at $41.6 million for FY2024, which was up 36.22% from $30.6 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Receivables - Net high stood at $41.6 million for FY2024, and its period low was $15.5 million during FY2021.
  • Over the past 3 years, Rigel Pharmaceuticals' median Receivables - Net value was $30.6 million (recorded in 2023), while the average stood at $30.7 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first spiked by 57.98% in 2020, then declined by 3.14% in 2021.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Receivables - Net stood at $16.0 million in 2020, then declined by 3.14% to $15.5 million in 2021, then rose by 29.27% to $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then surged by 36.22% to $41.6 million in 2024.